ASX
Paradigm Biopharmaceuticals Limited
PAR:ASX•Healthcare
Sensitive ASX Announcement
FIRST PATIENT DOSED IN MPS-I PHASE 2 CLINICAL TRIAL
Published: 12/11/20, 08:19am (AEST)•3 pages